Squarepoint
AXSM icon

Squarepoint’s Axsome Therapeutics AXSM Stock Holding History

Squarepoint’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.3M Sell
114,102
-40,898
-26% -$7.06M 0.02% 728
2025
Q4 		$28.3M Hold
155,000
– – 0.03% 594
2025
Q3 		$18.8M Sell
155,000
-8,000
-5% -$901K 0.02% 774
2025
Q2 		$17M Buy
163,000
+21,403
+15% +$2.27M 0.02% 844
2025
Q1 		$16.5M Buy
141,597
+52,167
+58% +$5.94M 0.02% 782
2024
Q4 		$7.57M Buy
+89,430
New +$8.22M 0.01% 1316
2024
Q1 		– Sell
-2,550
Closed -$203K – 4011
2023
Q4 		$203K Sell
2,550
-94,211
-97% -$6.3M ﹤0.01% 3586
2023
Q3 		$6.76M Buy
+96,761
New +$7.23M 0.02% 994
2023
Q1 		– Sell
-44,616
Closed -$3.44M – 3226
2022
Q4 		$3.44M Sell
44,616
-87,977
-66% -$5.26M 0.01% 1037
2022
Q3 		$5.92M Buy
132,593
+124,202
+1,480% +$6.21M 0.03% 658
2022
Q2 		$321K Buy
+8,391
New +$265K ﹤0.01% 2262
2021
Q4 		– Sell
-10,730
Closed -$354K – 3157
2021
Q3 		$354K Sell
10,730
-11,273
-51% -$439K ﹤0.01% 2166
2021
Q2 		$1.48M Buy
22,003
+9,474
+76% +$569K 0.01% 1359
2021
Q1 		$709K Buy
+12,529
New +$881K ﹤0.01% 1767
2020
Q2 		– Sell
-18,234
Closed -$1.07M – 2225
2020
Q1 		$1.07M Buy
18,234
+7,937
+77% +$647K 0.03% 694
2019
Q4 		$1.06M Buy
+10,297
New +$416K 0.01% 1290
2019
Q3 		– Sell
-37,706
Closed -$971K – 2338
2019
Q2 		$971K Buy
+37,706
New +$756K 0.01% 1274
2018
Q1 		– Sell
-31,400
Closed -$176K – 1686
2017
Q4 		$176K Sell
31,400
-2,200
-7% -$11.1K ﹤0.01% 1830
2017
Q3 		$186K Buy
+33,600
New +$180K ﹤0.01% 1405

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's AXSM Position: Q1 2026 in Review

Squarepoint reduced its Axsome Therapeutics (AXSM) stake by 26% in Q1 2026, selling an estimated $7.06M and leaving 114,102 shares worth $19.3M. The position accounts for 0.02% of the portfolio, ranked #728.

Squarepoint first reported a position in AXSM in Q3 2017 and has held it in 19 quarters since. The position peaked at $28.3M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Squarepoint held 114,102 shares of Axsome Therapeutics worth $19.3M as of Q1 2026.
  • Squarepoint sold 40,898 Axsome Therapeutics shares in Q1 2026, an estimated $7.06M.
  • Axsome Therapeutics made up 0.02% of Squarepoint's portfolio in Q1 2026, its #728 holding.
  • Squarepoint first reported a position in Axsome Therapeutics in Q3 2017 and has held it in 19 quarters since.
  • Squarepoint's Axsome Therapeutics position peaked at $28.3M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.